Therapeutic modulation of the tumor inflammatory response

Details Therapeutic modulation of the tumor inflammatory response Therapeutic modulation of the tumor inflammatory response

2006-05-09

2006-05-09

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S085100, C424S085200, C424S085400, C424S093210, C424S094630, C424S094640, C424S094650, C424S094660, C424S277100, C424S530000, C424S534000

Reexamination Certificate

active

07041302

ABSTRACT:
The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1 inflammatory response in the tumor tissue, whereby the tumor tissue is diminished or destroyed and the patient develops immune memory that inhibits or prevents recurrence of the tumor.

REFERENCES:
patent: 4879111 (1989-11-01), Chong
patent: 5082658 (1992-01-01), Palladino
patent: 5446033 (1995-08-01), Engel et al.
patent: 5474981 (1995-12-01), Luster et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 6011047 (2000-01-01), Semple et al.
patent: 2002/0044919 (2002-04-01), Yu
patent: 2002/0090381 (2002-07-01), Bottomly et al.
patent: 310136 (1997-02-01), None
patent: WO 92/01039 (1992-01-01), None
patent: WO 98/36768 (1998-08-01), None
patent: 99/59599 (1999-11-01), None
patent: 00/01392 (2000-01-01), None
patent: 01/62274 (2001-08-01), None
Mori, et al., 1993, Int J Gynecol Cancer 3(1):36-43.
Zeisig, et al., 1994, Anticancer Res, 14(5A):1785-9.
Wuyts, et al., 1994, J Immunol Methods, 174(1-2):237-47.
Akatov, et al., 2000, Biosci Rep, 20(5):411-7.
Schrauzer, 2000, Cell Mol Life Sci, 57(13-14):1864-73.
Demer, et al., BIOTECHNOLOGY, vol. 12, p. 320, Mar. 1994.
Jain et al., Cancer and Metatasis Review, vol. 9, pp. 253-266.
Berke and Rosen, Transplantation Proceedings, 1987, vol. XIX, pp. 412-416).
abstract of Curtiss (Arteriosclerosis and Thrombosis, 1994, vol. 14, pp. 47-53).
U.S. Appl. No. 60/177,024, filed Jan. 19, 2000.
Nishimura et al (Cancer Chemother Pharmacol, 2000, vol. 46 (suppl.), pp. S52-S61).
Cameron et al (Journal of Experimental Medicine, 1990, vol. 171, pp. 249-263).
Ferrero et al (European Journal of Immunology, 1998, vol. 28, pp. 2530-2536).
Rovere et al (Journal of Immunology, 1998, vol. 161, pp. 4467-4471).
Mollinedo et al (Cancer Research, 1997, vol. 57, pp. 1320-1328).
Boggs et al (Biochimica et Biophysica Acta, 1998, vol. 1389, pp. 1-12).
Garcia-Zepeda et al (Nature Medicine, 1996, vol. 2, pp. 449-456).
Wang et al (Molecular and Cellular Biology, 1995, vol. 15, pp. 1759-1768).
Ausubel et al (Short Protocols in Molecular Biology, second edition, 1992 p. 1-20).
abstract of DeSanctis et al (Seminars in Interventional Radiology, 1997, vol. 14, pp. 255-284).
abstract of Aker (Cancer, 1979, vol. 43, suppl., pp. 2103-2107).
abstract of Johnston (Journal of Human Nutrition, 1979, vol. 33, pp. 189-196).
Tuting et al (Journal of Immunology, 1998, vol. 160, pp. 1139-1147).
Lee et al (J Immunol. Jan. 1, 2000: 164: 231-9).
Tannenbaum et al (J Immunol. 1998: 161: 927-932).
Lanni et al (Proc Natl Acad Sci USA vol. 94, pp. 9679-9683).
Chou et al (1997, Bioelectromagnetics, vol. 18, p. 14-24, abstract only).
Habal (1980, J Biomer Mater Res, vol. 14, pp. 789-801, abstract only).
Wemyss-Holden et al (2000, J Surg Res, vol. 93, pp. 55-62).
Tamai et al (2000, Oncol Rep, vol. 719, pp. 719-723), Abstract only Apr. 6, 2003.
Gallucci et al, 2001, Curr Opin Immunol, vol. 13, pp. 114-119.
Yamamoto et al (2003, Int J Cancer, vol. 103, p. 822 abstract only).
Dabrowska et al (2000, Anticancer Res, vol. 20, pp. 391-394 abstract only).
Kondoh et al (2003, Breast Cancer Res Treat, vol. 78, pp. 37-44).
Jaroszeski et al (1997, Biochim Biophys Acta, vol. 1334, pp. 15-18).
Svedersky L.P., et al. “Enhanced Antitumor Activity of Recombinant Interferon Gamma in Combination with Tumor Necrosis Factors and Chemotherapeutic Agents” International Journal of Immunopharmacology, vol. 7, No. 3, 1985, p. 330.
Lumsden, et al., “Improved efficacy of doxorubicin by simultaneous treatment with interferon and interleukin-2,” in vivo 6:553-8 (1992).
Akbar et al., “IFN-α and IFN-β: a link between immune memory and chronic inflammation,” Immunol. Today 21(7):337-342 (2000).
Asselin-Paturel et al., “Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and RBL of non-small cell lung cancer patients,” Int. J. Cancer 77(1):7-12 (1998) (Abstract only).
Azavedo et al., “Radiological evidence of response to electrochemical treatment of breast cancer,” Clin. Radiol. 43:84-87 (1991).
Baggiolini et al., “Human Chemokines: an update,” Annu. Rev. Immunol. 15:675-705 (1997).
Bellone et al., “Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients,” Am. J. Pathol. 155(2):537-547 (1999) (Abstract only).
Bendich, “New data on vitamin C intake,” Nutrition 13(2):154-155 (1997).
Bonagura et al., “Recurrent respiratory papillomatosis: altered CD8(+)T-cell subsets and T(H)1/T(H)2 cytokine imbalance,” Clin. Immunol. 93(3):302-311 (1999) (Abstract only).
Camp et al., “In situ cytokine production by breast cancer tumor-infiltrating lymphocytes,” Ann. Surg. Oncol. 3(2):176-184 (1996) (Abstract only).
Clive et al., “Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma,” Cancer Chemother. Pharmacol. 44 (Suppl):S29-S30 (1999).
Colantonio et al., “Upregulation of integrin α6/β1 and chemokine receptor CCR1 by Interleukin-12 promotes the migration of human type 1 helper T cells,” Blood 94(9):2981-2989 (1999).
Constant et al., “Induction of Th1 and Th2 CD4+T cell responses: The alternative approaches,” Annu. Rev. Immunol. 15:297-322 (1997).
Del Prete, “Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy,” Allergy 47(5):450-455 (1992) (Abstract only).
Del Prete, “The concept of type-1 and type-2 helper T cells and their cytokines in humans” Int. Rev. Immunol. 16(3-4):427-455 (1998) (Abstract only).
Echchakir et al., “Analysis of T-cell-receptor β-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas,” Int. J. Cancer 81:205-213 (1999).
Elsasser-Beile et al., “Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas,” Tumour Biol. 19(6):470-476 (1998) (Abstract only).
Fleischmann et al., “Systemic effects of orally administered interferons and interleukin-2,” J. Interferon Cytokine Res. 19:829-839 (1999).
Fujimoto et al., “Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state,” J. Immunol. 158(12):5619-5626 (1997) (Abstract only).
Fujisao et al., “Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma,” Br. J. Haematol. 103(2):308-310 (1998) (Abstract only).
Gallucci et al., “Danger signals: SOS to the immune system,” Curr. Op. Immunol. 13:114-119 (2001).
Ghosh et al., “Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth,” J. Natl. Cancer Inst. 87(19):1478-1483 (1995) (Abstract only).
Gingras et al., “Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue,” J. Neuroimmunol. 57(1-2):143-153 (1995) (Abstract only).
Gingras et al., “Little expression of Cytokine mRNA by fresh tumor-infiltrating mononuclear leukocytes from glioma and lung adenocarcinoma,” Cytokine 7(6):580-588 (1995).
Goedegebuure et al., “Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer,” Cellular Immunol. 175:150-156 (1997).
Gorelik et al., “Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor,” Cancer Immunol. Immunother. 39:117-126 (1994).
Gorelik et al., “Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapuetic outcome,” C

Affiliated with

Also associated with

Rating

Therapeutic modulation of the tumor inflammatory response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic modulation of the tumor inflammatory response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic modulation of the tumor inflammatory response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3530355